{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:53:47Z","timestamp":1789916027083,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:00:00Z","timestamp":1490227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:00:00Z","timestamp":1490227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1038\/leu.2017.93","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T08:20:59Z","timestamp":1490257259000},"page":"2365-2375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL"],"prefix":"10.1038","volume":"31","author":[{"given":"A M","family":"Savino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Sarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Vieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-8422","authenticated-orcid":false,"given":"G","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bugarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K L","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Gaipa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Izraeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L H","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G P","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Te Kronnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Palmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,23]]},"reference":[{"key":"BFleu201793_CR1","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children\u2019s oncology group. J Clin Oncol 2012; 30: 1663\u20131669.","journal-title":"J Clin Oncol"},{"key":"BFleu201793_CR2","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","volume":"376","author":"C Parker","year":"2010","unstructured":"Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010; 376: 2009\u20132017.","journal-title":"Lancet"},{"key":"BFleu201793_CR3","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.2011.34.8144","volume":"29","author":"J Hof","year":"2011","unstructured":"Hof J, Krentz S, van Schewick C, K\u00f6rner G, Shalapour S, Rhein P et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 3185\u20133193.","journal-title":"J Clin Oncol"},{"key":"BFleu201793_CR4","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","volume":"114","author":"LJ Russell","year":"2009","unstructured":"Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009; 114: 2688\u20132698.","journal-title":"Blood"},{"key":"BFleu201793_CR5","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2011-11-394221","volume":"119","author":"I Chen","year":"2012","unstructured":"Chen I, Harvey RC, Mullighan CG, Gastier-foster J, Wharton W, Kang H et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children\u2019s Oncology Group Study. Blood 2012; 119: 3512\u20133523.","journal-title":"Blood"},{"key":"BFleu201793_CR6","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","volume":"116","author":"RC Harvey","year":"2014","unstructured":"Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome Identification of nov. Blood 2014; 116: 4874\u20134884.","journal-title":"Blood"},{"key":"BFleu201793_CR7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ng.469","volume":"41","author":"CG Mullighan","year":"2009","unstructured":"Mullighan CG, Collins-underwood JR, Phillips LAA, Loudin MG, Liu W, Zhang J et al. Rearrangement of CRLF2 in B-progenitor \u2013 and Down syndrome \u2013 associated acute lymphoblastic leukemia. Nat Genet 2009; 41: 1243\u20131246.","journal-title":"Nat Genet"},{"key":"BFleu201793_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","volume":"115","author":"L Hertzberg","year":"2010","unstructured":"Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010; 115: 1006\u20131017.","journal-title":"Blood"},{"key":"BFleu201793_CR9","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1128\/MCB.24.6.2584-2592.2004","volume":"24","author":"N Carpino","year":"2004","unstructured":"Carpino N, Thierfelder WE, Chang M, Turner SJ, Ziegler SF, Ihle JN et al. Absence of an essential role for thymic stromal lymphopoietin receptor in murine B-cell development absence of an essential role for thymic stromal lymphopoietin receptor in murine B-cell development. Mol Cell Biol 2004; 24: 2584\u20132592.","journal-title":"Mol Cell Biol"},{"key":"BFleu201793_CR10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","volume":"2","author":"SK Tasian","year":"2012","unstructured":"Tasian SK, Doral MY, Borowitz MJ, Wood BL, Chen I, Harvey RC et al. Aberrant STAT5 and PI3K \/ mTOR pathway signaling occurs in human CRLF2 -rearranged B-precursor acute lymphoblastic leukemia. Blood 2012; 2: 833\u2013843.","journal-title":"Blood"},{"key":"BFleu201793_CR11","doi-asserted-by":"publisher","first-page":"9414","DOI":"10.1073\/pnas.0811761106","volume":"106","author":"CG Mullighan","year":"2009","unstructured":"Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman Ba, Phillips La et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106: 9414\u20139418.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201793_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1073\/pnas.0911726107","volume":"107","author":"A Yoda","year":"2010","unstructured":"Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010; 107: 252\u2013257.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201793_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/10799899909036638","volume":"19","author":"MH Heim","year":"1999","unstructured":"Heim MH . The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res 1999; 19: 75\u2013120.","journal-title":"J Recept Signal Transduct Res"},{"key":"BFleu201793_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054\u20131061.","journal-title":"Lancet"},{"key":"BFleu201793_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","volume":"22","author":"KG Roberts","year":"2012","unstructured":"Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012; 22: 153\u2013166.","journal-title":"Cancer Cell"},{"key":"BFleu201793_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1084\/jem.20111694","volume":"209","author":"O Weigert","year":"2012","unstructured":"Weigert O, Lane Aa, Bird L, Kopp N, Chapuy B, van Bodegom D et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012; 209: 259\u2013273.","journal-title":"J Exp Med"},{"key":"BFleu201793_CR17","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/pbc.24133","volume":"58","author":"S Maude","year":"2012","unstructured":"Maude S, Tasian S, Vincent T, Hall J, Roberts K, Collins R et al. Targeting JAK2 and mtor in xenograft models of crlf2-overexpressing acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer 2012; 58: 1014.","journal-title":"Pediatr Blood Cancer"},{"key":"BFleu201793_CR18","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Dolai S, Delgado-martin C, Vincent T, Robbins A, Selvanathan A et al. Efficacy of JAK \/ STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood 2015; 125: 1759\u20131768.","journal-title":"Blood"},{"key":"BFleu201793_CR19","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1182\/blood-2014-05-576652","volume":"124","author":"L Springuel","year":"2014","unstructured":"Springuel L, Hornakova T, Losdyck E, Lambert F, Leroy E, Constantinescu SN et al. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood 2014; 124: 3924\u20133931.","journal-title":"Blood"},{"key":"BFleu201793_CR20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","volume":"150","author":"A Rambaldi","year":"2010","unstructured":"Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010; 150: 446\u2013455.","journal-title":"Br J Haematol"},{"key":"BFleu201793_CR21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/bjh.12332","volume":"161","author":"G Finazzi","year":"2013","unstructured":"Finazzi G, Vannucchi AM, Martinelli V, Ruggeri M, Nobile F, Specchia G et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol 2013; 161: 688\u2013694.","journal-title":"Br J Haematol"},{"key":"BFleu201793_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/sj.leu.2405049","volume":"22","author":"V Guerini","year":"2008","unstructured":"Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008; 22: 740\u2013747.","journal-title":"Leukemia"},{"key":"BFleu201793_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/1120009X.2016.1145375","volume":"28","author":"SA Ganai","year":"2016","unstructured":"Ganai SA . Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies. J Chemother 2016; 28: 247\u2013254.","journal-title":"J Chemother"},{"key":"BFleu201793_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00277-009-0793-8","volume":"89","author":"M Galli","year":"2010","unstructured":"Galli M, Salmoiraghi S, Golay J, Gozzini A, Crippa C, Pescosta N . A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 2010; 89: 185\u2013190.","journal-title":"Ann Hematol"},{"key":"BFleu201793_CR25","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/art.30238","volume":"63","author":"J Vojinovic","year":"2011","unstructured":"Vojinovic J, Damjanov N, D\u2019Urzo C, Furlan A, Susic G, Pasic S et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2011; 63: 1452\u20131458.","journal-title":"Arthritis Rheum"},{"key":"BFleu201793_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica P, Petrini S, Oria VD, Amico AD, Catteruccia M, Pane M et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2016; 26: 643\u2013649.","journal-title":"Neuromuscul Disord"},{"key":"BFleu201793_CR27","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1093\/nar\/gkv188","volume":"43","author":"S Pinz","year":"2015","unstructured":"Pinz S, Unser S, Buob D, Fischer P, Jobst B, Rascle A . Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function. Nucleic Acids Res 2015; 43: 3524\u20133545.","journal-title":"Nucleic Acids Res"},{"key":"BFleu201793_CR28","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.exphem.2012.04.007","volume":"40","author":"A Amaru Calzada","year":"2012","unstructured":"Amaru Calzada A, Todoerti K, Donadoni L, Pellicioli A, Tuana G, Gatta R et al. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2 V617F myeloproliferative neoplasm cells. Exp Hematol 2012; 40: 634\u2013645.","journal-title":"Exp Hematol"},{"key":"BFleu201793_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.a.10072","volume":"55A","author":"PO Krutzik","year":"2003","unstructured":"Krutzik PO, Nolan GP . Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytom Part A 2003; 55A: 61\u201370.","journal-title":"Cytom Part A"},{"key":"BFleu201793_CR30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","volume":"47","author":"WR Greco","year":"1995","unstructured":"Greco WR, Bravo G, Parsons JC . The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47: 331\u2013385.","journal-title":"Pharmacol Rev"},{"key":"BFleu201793_CR31","first-page":"5165","volume":"60","author":"LM Butler","year":"2000","unstructured":"Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-cardo C et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo 1. Cancer Res 2000; 60: 5165\u20135170.","journal-title":"Cancer Res"},{"key":"BFleu201793_CR32","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R . FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247\u20131252.","journal-title":"Oncologist"},{"key":"BFleu201793_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3324\/haematol.2014.114447","volume":"100","author":"C Bugarin","year":"2015","unstructured":"Bugarin C, Sarno J, Palmi C, Savino AM, te Kronnie G, Dworzak M et al. Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B cell precursor acute lymphoblastic leukemia. Haematologica 2015; 100: 229\u2013232.","journal-title":"Haematologica"},{"key":"BFleu201793_CR34","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","volume":"372","author":"D Bercovich","year":"2008","unstructured":"Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down\u2019s syndrome. Lancet 2008; 372: 1484\u20131492.","journal-title":"Lancet"},{"key":"BFleu201793_CR35","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","volume":"115","author":"V Conter","year":"2010","unstructured":"Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Gr\u00fcmayer R, M\u00f6ricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206\u20133214.","journal-title":"Blood"},{"key":"BFleu201793_CR36","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2013.245","volume":"28","author":"JaP Spijkers-Hagelstein","year":"2014","unstructured":"Spijkers-Hagelstein JaP, Pinhan\u00e7os SS, Schneider P, Pieters R, Stam RW . Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL. Leukemia 2014; 28: 761\u2013769.","journal-title":"Leukemia"},{"key":"BFleu201793_CR37","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.1158\/1078-0432.CCR-13-0905","volume":"19","author":"E Evrot","year":"2013","unstructured":"Evrot E, Ebel N, Romanet V, Roelli C, Andraos R, Qian Z et al. JAK1\/2 and pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. Clin Cancer Res 2013; 19: 6230\u20136241.","journal-title":"Clin Cancer Res"},{"key":"BFleu201793_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature11303","volume":"489","author":"P Koppikar","year":"2012","unstructured":"Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012; 489: 155\u2013159.","journal-title":"Nature"},{"key":"BFleu201793_CR39","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/leu.2011.278","volume":"26","author":"D Stumpel","year":"2012","unstructured":"Stumpel D, Schneider P, Seslija L, Osaki H, Williams O, Pieters R et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia 2012; 26: 682\u2013692.","journal-title":"Leukemia"},{"key":"BFleu201793_CR40","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1182\/blood-2012-01-401687","volume":"119","author":"T Bhatla","year":"2012","unstructured":"Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 2012; 119: 5201\u20135210.","journal-title":"Blood"},{"key":"BFleu201793_CR41","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-14-1290","volume":"21","author":"MC Stubbs","year":"2015","unstructured":"Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J et al. Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL. Clin Cancer Res 2015; 21: 2348\u20132358.","journal-title":"Clin Cancer Res"},{"key":"BFleu201793_CR42","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.18632\/oncotarget.2992","volume":"6","author":"BR Beagle","year":"2014","unstructured":"Beagle BR, Nguyen DM, Mallya S, Tang SS, Lu M, Zeng Z et al. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget 2014; 6: 2088\u20132100.","journal-title":"Oncotarget"},{"key":"BFleu201793_CR43","doi-asserted-by":"publisher","first-page":"e2047","DOI":"10.1038\/cddis.2015.394","volume":"6","author":"M Pinazza","year":"2016","unstructured":"Pinazza M, Borga C, Agnusdei V, Minuzzo S, Fossati G, Paganin M et al. An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts. Cell Death Dis 2016; 6: e2047.","journal-title":"Cell Death Dis"},{"key":"BFleu201793_CR44","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/pbc.25575","volume":"62","author":"ML Loh","year":"2015","unstructured":"Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children\u2019s Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer 2015; 62: 1717\u20131724.","journal-title":"Pediatr Blood Cancer"},{"key":"BFleu201793_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2013-07-453480","volume":"123","author":"S Izraeli","year":"2014","unstructured":"Izraeli S, Vora A, Zwaan CM, Whitlock J . How I treat all in down\u2019s syndrome: pathobiology and management. Blood 2014; 123: 35\u201340.","journal-title":"Blood"},{"key":"BFleu201793_CR46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/leu.2013.264","volume":"28","author":"MV Stankov","year":"2014","unstructured":"Stankov MV, El Khatib M, Kumar Thakur B, Heitmann K, Panayotova-Dimitrova D, Schoening J et al. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia 2014; 28: 577\u2013588.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201793.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201793","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.93","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu201793.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T16:20:00Z","timestamp":1750177200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,23]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["BFleu201793"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.93","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,23]]},"assertion":[{"value":"10 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GF is an employee of Italfarmaco SpA. GPN is a paid consultant for Fluidigm, the manufacturer that produced some of the reagents and instrumentation used in this manuscript. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}